British pharmaceutical giant GSK and the entire UK drugmaking sector have been left in limbo following Donald Trump’s threat to levy 100% tariffs on their products, despite a recent charm offensive from London. The move demonstrates that high-level diplomacy, including a state visit and a banquet hosted by King Charles, has failed to secure protection for one of the UK’s most critical industries.
The announcement has created a sense of crisis, as the pharmaceutical sector was a notable omission from the US tariff deal arranged by Keir Starmer five months ago. That agreement centered on cars, steel, and aerospace, leaving drug companies exposed. A UK government spokesperson expressed understanding for the industry’s concern and confirmed that diplomatic efforts to de-escalate the situation are now a top priority.
The new tariffs, set to be implemented on October 1st, also include a 25% tax on heavy-duty trucks and a 50% tax on cabinets, affecting a wide range of European exporters. However, the 100% rate on branded drugs is by far the most severe, representing a potentially existential threat to UK companies heavily reliant on the US market. The threat also contradicts a personal pledge from Trump in May to give the UK “preferential treatment.”
A potential silver lining has been identified by market analysts, who believe the policy is aimed at boosting US manufacturing. The tariffs may not apply to companies with a physical production presence in the United States. Lale Akoner of eToro suggests that global firms like AstraZeneca and Novartis, which are investing in US plants, are “out of the firing line.” This theory suggests the policy is a powerful incentive for foreign direct investment.
Regardless of the ultimate scope, the threat has already had repercussions. European truck makers saw their shares fall, and industry bodies like Germany’s VDA have voiced strong opposition, calling the tariffs “incomprehensible.” The situation has left many businesses, including Sweden’s Ikea, “closely monitoring the evolving situation” as they navigate the increasingly complex and unpredictable landscape of global trade.